Process for preparing salt of hyaluronic acid with a pharmaceutically active substance

• US 4,736,024 A
• Filed: 04/03/1986
• Issued: 04/05/1988
• Est. Priority Date: 04/05/1985
• Status: Expired due to Term

• Current Assignee: Fidia Farmaceutici s.p.a (P.&R. S.p.A)
• Original Assignee: Fidia S.P.A.
• Inventors: Della Valle, Francesco, Romeo, Aurelio, Lorenzi, Silvana
• Primary Examiner(s): Brown, J. R.
• Assistant Examiner(s): PESELEV, ELLI
• Application Number:
  US06/847,632
• Time in Patent Office: 733 Days
• Field of Search: 536/54, 536/55.3, 536/55.2, 536/18.7, 536/101, 536/121
• US Class Current: 536/55.3
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08B 37/0072 Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Abstract

Pharmaceutical preparations for topical administration containing a pharmacologically active substance together with hyaluronic acid or a molecular weight fraction thereof. The hyaluronic acid may be in the form of the free acid or may be a salt with an alkali or alkaline earth metal, magnesium, aluminum or ammonium, or in the form of a salt with one or more pharmacologically active substances.

Claims

1. A process for the preparation of a salt of hyaluronic acid with a pharmaceutically active substance which comprises:

(a) combining an aqueous solution of a barium salt of hyaluronic acid with a sulfate of a pharmaceutically active substance; and

(b) separating the precipitated barium sulfate to obtain the salt of hyaluronic acid with a pharmaceutically active substance in aqueous solution.

2. A process according to claim 1, wherein said sulfate is added in an amount such that the number of sulfate equivalents is equal to the number of hyaluronic acid equivalents, thereby producing a stoichiometrically neutral hyaluronic acid salt.

3. A process according to claim 1, wherein said sulfate is added in an amount such that the number of sulfate equivalents is less than the number of hyaluronic acid equivalents, thereby producing a partially salified hyaluronic acid salt.

4. A process according to claim 1, wherein said barium salt of hyaluronic acid is further combined with a sulfate of at least one member selected from the group consisting of an alkali or alkaline earth metal, aluminum or ammonium.

5. A process according to claim 4, wherein said sulfates are added in an amount such that the number of sulfate equivalents is equal to the number of hyaluronic acid equivalents.

6. A process according to claim 4, wherein said sulfates are added in an amount such that the number of sulfate equivalents is less than the number of hyaluronic acid equivalents.

7. A process according to claim 1, wherein said active substance is at least one member selected from erythromycin, gentamycin, neomycin, streptomycin, dihydrostreptomycin, kanamycin, amikacyn, tobramycin, aureomycin, spectinomycin, erythromycin, oleandomycin, carbomycin, spiramycin, oxytetracycline, rolitetracycline, bacitracin, polymyxin B, gramicidin, colistin, chloramphenicol, lincomycin, amphotericin B, griseofulvin, nystatin, diethylcarbamazine, mebendazol, sulfacetamide, sulfadiazine, sulfisoxazole, iodeoxyuridine, adenine arabinoside, tricarpine, metacholine, carbamylcholine, aceclidine, fisostigmine, neostigmine, demacarium, stropina, propanolol timolol, pindolol, bupranolol, atenolol, metoprolol, oxprenolol, practolol, butoxamine, sotalol, butadrine, labetalol, dexamethasone, triamcinolone, prednisolone, fluorometholone and medrison.

8. A process according to claim 1, wherein the hyaluronic acid is a molecular weight fraction having a molecular weight of between about 90-80% and 0.23% of the molecular weight of integral hyaluronic acid having a molecular weight of 13 million.

9. A process according to claim 8, wherein the hyaluronic acid fraction is substantially free of hyaluronic acid having a molecular weight less than about 30,000.

10. A process according to claim 9, wherein the molecular weight fraction has an average molecular weight of about 50,000 to about 100,000, about 500,000 to about 730,000 or about 250,000 to about 350,000.

11. A process according to claim 1, wherein said pharmaceutically active substance is a substance suitable for topical administration.

12. A process according to claim 1, wherein the active substance has ophthalmological or dermatological activity.

13. A process for the preparation of a barium salt of hyaluronic acid or a molecular weight fraction thereof which comprises

(a) treating a cetylpyridinium salt of hyaluronic acid or a molecular weight fraction thereof with an aqueous solution of barium chloride;

and

(b) separating the aqueous solution and adding ethanol to thereby precipitate the barium salt of hyaluronic acid or of a molecular weight fraction thereof.

14. A process according to claim 13, wherein the hyaluronic acid fraction is substantially free of hyaluronic acid having a molecular weight less than about 30,000.

15. A process according to claim 13, wherein said molecular weight fraction has an average molecular weight of about 50,000 to about 100,000, about 500,000 to about 730,000 or about 250,000 to about 350,000.